Evidence map›Paper›PMID 37728654›Full record

ArticleWiener klinische Wochenschrift2023

[General recommendations for the management of glomerular diseases-2023].

Martin Windpessl, Philipp Gauckler, Emanuel Zitt, Karl Lhotta, Cihan Ay, Kathrin Eller, Balazs Odler, Irmgard Neumann, Michael Rudnicki, Andreas Kronbichler and 1 more

Open access · hybridAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Martin WindpesslMedizinische Fakultät, JKU, Linz, Österreich.
Philipp GaucklerDepartment Innere Medizin IV (Nephrologie und Hypertensiologie), Medizinische Universität Innsbruck, Innsbruck, Österreich.
Emanuel ZittAbteilung für Innere Medizin III (Nephrologie, Dialyse und Hypertensiologie), Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, Österreich.
Karl LhottaAbteilung für Innere Medizin III (Nephrologie, Dialyse und Hypertensiologie), Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, Österreich.
Cihan AyKlinische Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Wien, Österreich.
Kathrin EllerKlinische Abteilung für Nephrologie, Abteilung für Innere Medizin III (Nephrologie, Dialyse und Hypertensiologie), Medizinische Universität Graz, Graz, Österreich.
Balazs OdlerKlinische Abteilung für Nephrologie, Abteilung für Innere Medizin III (Nephrologie, Dialyse und Hypertensiologie), Medizinische Universität Graz, Graz, Österreich.
Irmgard NeumannVasculitis.at, Wien, Österreich.
Michael RudnickiDepartment Innere Medizin IV (Nephrologie und Hypertensiologie), Medizinische Universität Innsbruck, Innsbruck, Österreich.
Andreas KronbichlerDepartment Innere Medizin IV (Nephrologie und Hypertensiologie), Medizinische Universität Innsbruck, Innsbruck, Österreich. andreas.kronbichler@i-med.ac.at.
Marcus D Säemann6. Medizinische Abteilung mit Nephrologie & Dialyse, Klinik Ottakring, Wien, Österreich.
Innsbruck Medical University · ATLandeskrankenhaus Feldkirch · ATMedical University of Graz · ATImmunologie-Zentrum Zürich · CHKlinikum Wels-Grieskirchen · ATMedical University of Vienna · ATUniversitätszahnklinik Wien · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glomerular diseases are associated with extrarenal complications, such as thromboembolism, cardiovascular events and particularly infections. A thorough knowledge of the various immunosuppressants and their associated toxicity profile is therefore of great importance. While nephrologists usually have extensive experience with calcineurin inhibitors and antimetabolites, two other compounds (rituximab, in severe cases cyclophosphamide) are used comparatively infrequently and will be discussed in more detail. Moreover, practical recommendations for the prevention of thromboembolism in states of nephrosis and for the prophylaxis of Pneumcystic jirovecii pneumonia are provided.

Indexed as

Nephrotic SyndromeThromboembolismCyclophosphamideHumansCyclophosphamideCyclophophamideNephrotic syndromePneumocystis jiroveciiRituximabThromboembolism

Identifiers

PMID37728654
PMCPMC10511582
OpenAlexW4386878070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.